GSK backs out of Ulverston site investment

Pharmaceutical giant, GSK, has backed out of its formerly proposed £350million investment into its site at Ulverston, Cumbria. The funds were going to a new biopharma drugs facility.

View all 3 updates ›

South Lakes council 'shocked' at GlaxoSmithKline's Ulverston investment back out

GSK will no longer be investing in its Ulverston site Credit: GSK

South Lakeland District Council (SLDC) say they are 'shocked and disappointed' at pharmaceutical giant, GlaxoSmithKine's (GSK) decision to pull out its investment from its Ulverston site in Cumbria.

SLDC’s portfolio holder for the economy, Councillor Graham Vincent, said the news was a blow. He said the council's concern now is to understand the implications for the future of the current site and the existing GSK employees in Ulverston.

The SLDC's chief executive spoke to GSK management who have said there will be no immediate impact on the existing workforce and the site does remain profitable. The council have said they will assist the company in finding a buyer, to continue the operation of the facility, should they decide to sell up.

We have been in meetings and discussions with GSK in the last few weeks about unrelated matters and there was no suggestion that this announcement was on the horizon. We will work with the company, the local MP, town, county and district councillors and Cumbria LEP to offer whatever support is necessary.

– Councillor Graham Vincent, South Lakes District Council Economy Portfolio Holder

More top news